Immutep Stock Discussion

$Immutep (IMMP.US)$
Patient Enrolment Completed for EFTISARC-NEO Phase II Trial
Wednesday, 22nd January at 8:00 am
Phase II trial evaluating efti in combination with radiotherapy plus KEYTRUDA® (pembrolizumab) in patients with soft tissue sarcoma reaches enrolment target of 40 patients
Data updates from EFTISARC-NEO expected in 2025
SYDNEY, AUSTRALIA, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology co...

$Immutep (IMMP.US)$ Immutep (ASX:IMM) said the phase 1 INSIGHT-003 trial reached an enrollment target of about 50 patients across Germany, according to a Monday Australian bourse filing.
INSIGHT-003 is an investigator-initiated study led by the Frankfurt Institute of Clinical Cancer Research IKF evaluating a triple combination therapy in first-line non-small cell lung cancer patients.
It is testing eftilagimod alpha in combination with antiPD-1 therapy, pembrolizumab, and doublet chemoth...

$Immutep (IMMP.US)$ Immutep Reports Initial Safety Data For IMP761, The First LAG-3 Agonist, In Phase I Trial With No Treatment-Related Adverse Events; Additional Data Expected In H1 2025 To Support Autoimmune Disease Treatment Potential

$Immutep (IMMP.US)$
Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II
Monday, 16th December at 8:00 am
• Findings published in Science Immunology resolve how human LAG-3 binds to its main ligand providing a better foundation for development of blocking LAG-3 therapeutics, including Immutep's anti-LAG-3 small molecule program
• Data also supports eftilagimod alfa's (efti) preferential binding to a subset of MHC Class II molecules on anti...

$Immutep (IMMP.US)$ Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II

$Immutep (IMMP.US)$
Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024
Immutep (NASDAQ: IMMP) has announced promising clinical results from Cohort B of the TACTI-003 Phase IIb trial, evaluating eftilagimod alpha (efti) combined with KEYTRUDA® in head and neck cancer patients. The study shows significant improvements in patients with PD-L1 CPS <1 expression, including:
- Median overall survival (OS) not yet reached with 67% 12-month OS rate
- Progression-fr...

$Immutep (IMMP.US)$ Another possible explosion... I hope.

$Immutep (IMMP.US)$ Immutep Says Phase 2B Trial of Head, Neck Cancer Combination Therapy Shows 'Strong' Overall Survival; Shares Up 3%

$Immutep (IMMP.US)$ Finally you show signs of awake...

$Immutep (IMMP.US)$ SYDNEY, AUSTRALIA, Dec. 10, 2024 -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the initiation of the pivotal TACTI-004 Phase III clinical trial for the treatment of first-line metastatic non-small cell lung cancer (1L NSCLC).
“The receipt of regulatory approval from the Australian Therapeutic Goods Administration t...